Founded in 2001, Cell>Point is a privately held biopharmaceutical company that is developing and commercializing intra-nuclear molecular imaging and therapeutic compounds for imaging cancer, diabetes, and cardiovascular disease, and the treatment of solid tumor and certain blood borne cancers using platform technologies licensed from The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”), Houston, Texas.
- Targeting the Hexosamine Biosynthetic Pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma
- Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology
7120 E. Orchard Rd., Suite 350
Centennial, Colorado 80111